Abstract
Most colorectal carcinomas harbor genetic alterations that result in stabilization of β-catenin. A colorectal carcinoma cell line, HCT116, which has both mutated and wild-type β-catenin genes, was engineered by homologous recombination to investigate the significance of β-catenin gene mutation. As expected, the mutant allele-targeted clones showed decreased β-catenin expression and downregulation of T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription. Morphologically, targeted clones were only minimally altered under usual culture conditions, but under low serum conditions, mutant allele-targeted clones still grew in plane, in contrast to parental cell line and wild allele-targeted clones, which formed spheroids. The mutant allele-targeted clones showed no significant changes in growth rate and anchorage-independent growth in vitro, and displayed rather increased growth in vivo. Although β-catenin stabilization affects some biological characteristics including adhesive properties, it may not have growth-promoting effects at least in some colorectal carcinomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis B, Matrisian LM . 1999 Oncogene 18: 2883–2891
Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM . 1999 EMBO J. 18: 5931–5942
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW . 1998 Science 281: 1509–1512
Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC . 2000 J. Clin. Invest. 106: 533–539
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN . 2000 Nat. Genet. 26: 146–147
Mariadason JM, Bordonaro M, Aslam F, Shi L, Kuraguchi M, Velcich A, Augenlicht LH . 2001 Cancer Res. 61: 3465–3471
Nagasawa Y, Miyoshi Y, Iwao K, Shinomura Y, Matsuzawa Y, Nakamura Y . 1999 Cancer Res. 59: 3539–3542
Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S . 2001 Cancer Res. 61: 2751–2758
Orford K, Orford CC, Byers SW . 1999 J. Cell Biol. 146: 855–868
Polakis P . 2000 Genes Dev. 14: 1837–1851
Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA . 2001 Cancer Res. 61: 6563–6568
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Mutata M, Shimano T, Yamaoka Y, Nakamura Y . 2000 Nat. Genet. 24: 245–250
Sedivy JM, Dutriaux A . 1999 Trend Genet. 15: 88–90
Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, Hirohashi S . 2002 Virchows. Arch. 440: 381–386
Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T, Toyoshima K, Kanamaru R, Kanegae Y, Saito I, Nakamura Y, Noda T . 1997 Science 278: 120–123
Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B . 2001 Cancer Res. 61: 818–822
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T . 1993 Science 260: 85–88
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW . 1998 Cancer Res. 58: 1130–1134
Tetsu O, McCormick F . 1999 Nature 398: 422–426
Wagenaar RA, Crawford HC, Matrisian LM . 2001 Cancer Res. 61: 2097–2104
Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM . 1997 Proc. Natl. Acad. Sci. USA 94: 1402–1407
Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S . 2000 Cancer Res. 60: 4761–4766
Acknowledgements
We thank Drs Gen Fujii, Tesshi Yamada, Yasuyoshi Naishiro and Masaaki Takamura for technical advice. This work was supported in part by a Grant-in-Aid for Second Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sekine, S., Shibata, T., Sakamoto, M. et al. Target disruption of the mutant β-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene 21, 5906–5911 (2002). https://doi.org/10.1038/sj.onc.1205756
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205756
Keywords
This article is cited by
-
Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma
Cellular Oncology (2018)
-
Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth
Journal of Biomedical Science (2011)
-
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
Modern Pathology (2011)
-
Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin
Oncogene (2011)
-
β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast
Modern Pathology (2010)